Receptos LLC

GAITHERSBURG, MD / ACCESSWIRE / December 6, 2023 / Remedy Plan Therapeutics ("Remedy Plan"), a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, is pleased to announce the expansion of its leadership team with the appointment of Cassandra Choe-Juliak, M.D., M.S., as the acting Chief Medical Officer (CMO). Dr. Choe-Juliak has more than 17 years of experience in biopharma, most recently as the Chief Medical Officer at Flame Biosciences and at Tiga Therapeutics. She has previously held leadership positions in clinical development at Affimed and Karyopharm Therapeutics. At Karyopharm Therapeutics, she helped lead the clinical development strategy for Selinexor, a first-in-class XPO1 inhibitor in multiple myeloma. "This appointment comes at a pivotal time for Remedy Plan, as we finalize our IND-enabling studies for our hyperbolic NAMPT inhibitor, RPT1G," said Greg Crimmins, Ph.D., CEO and Founder of Remedy Plan Therapeutics. "We are thrilled to welcome Dr. Choe-Juliak to the team. Her extensive background in oncology clinical development and proven track record in advancing therapeutics to the clinic will be important as we begin our clinical program." "Remedy Plan's unique approach is the first that enables the partial inhibition of NAMPT. This allows for cancer cell growth inhibition without the on-target toxicities that have been seen with other NAMPT inhibitors," said Dr. Choe-Juliak. "I am inspired by the pioneering research and excited to help bring RPT1G to patients." Alongside the expansion of its leadership team, Remedy Plan also announced the expansion of its board of directors with the addition of Christian Waage, JD as an Independent Director. Mr. Waage is a biotech executive with more than two decades of experience in the industry. He is currently EVP, Technical Operations and Administration at Gossamer Bio Inc. and has previously held executive positions at Ardea Biosciences, Inc., Receptos Inc. and Celgene Corporation. About Remedy Plan Therapeutics Remedy Plan is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for allosteric inhibition of NAMPT that is fractional and highly tunable. NAMPT is an enzyme that controls how cells use energy and is core to human biology. NAMPT dysregulation is responsible for more than 20 diseases. Efforts to reduce NAMPT activity to date have resulted in unmanageable toxicities to healthy cells due to the dual role of NAMPT in healthy cell functioning and disease. Remedy Plan's groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. Remedy Plan is advancing a robust pipeline of tunable NAMPT inhibitors to address NAMPT dysregulation in solid tumors, hematologic malignancies, obesity, and autoimmune disorders. About RPT1G, a novel oncology therapeutic Remedy Plan's lead asset is RPT1G, a clinical drug candidate for the treatment of hematological malignancies. RPT1G has a unique, first-in-class mechanism of action that is optimized to preserve the cellular metabolism in healthy cells, while inhibiting activity in malignant cells. With a favorable efficacy and tolerability pro animals, RPT1G will be advancing to the clinic in 2024. For more information, please visit and follow Remedy Plan on social media: Contact: Parisa Moghaddam-Taaheri, Ph.D. parisa@remedyplan.com, (240) 408-4854 SOURCE: Remedy Plan Therapeutics View source version on accesswire.com:

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Longtime BioMarin CEO hands baton off to Genentech chief BioMarin In pharma executive leadership terms, 18 years is an eternity. For comparison, that’s longer than the entire tenure of Robert Bradway at Amgen, who himself is a pharmaceutical staple.  But such was the length of Jean-Jacques Bienaimé’s tenure at the helm of BioMarin. Still, all good things must come to an end, and Bienaimé is hanging it up. The rare disease drug developer is not looking far for a replacement. Taking over will be Genentech CEO Alexander Hardy, from a company headquartered just a few miles south of BioMarin’s Marin County campus. BioMarin says the announcement followed a “multi-year succession planning process.” Hardy takes over a company that in the years since Bienaimé’s appointment has grown to about 3,000 employees and three commercial products. BioMarin recently reported $581.3 million in third-quarter earnings, a 15% increase compared to the same period a year ago.  Genentech will, for now, stick with interim CEO Ashley Magargee, who leads the U.S. commercial portfolio. She’s been temporarily guiding the company since Hardy’s “recent sabbatical.” Fierce Pharma  J&J’s cancer R&D chief to retire  Johnson & Johnson J&J’s oncology R&D team is transitioning from the leadership of Peter Lebowitz, M.D., Ph.D., to Yusri Elsayed, M.D., Ph.D., effective Jan. 1, 2024. The healthcare giant said Lebowitz will retire after a “remarkable career” that included overseeing a group that delivered 14 novel medicines.  He oversaw work on therapies such as small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics and immuno-oncology therapies. Lebowitz’s efforts also helped J&J secure dozens of deals in key indications.  Elsayed, meanwhile, will rise from his role as vice president and head of the hematologic malignancies group at J&J. He has worked at the company for more than 18 years. Prior to J&J, he briefly worked at Bristol Myers Squibb. Release Viridian taps ex-Magenta CFO for chief executive job  Viridian Therapeutics  Magenta Therapeutics had a tough go of it after the death of a patient in a clinical trial halted the study and ultimately spurred the closure of the entire company. Now, one executive of the company has found a new landing spot.  Stephen Mahoney, Magenta’s former chief financial and operating officer, has been named the CEO of Viridian Therapeutics and a member of the board. Before Magenta, Mahoney was the president and chief operating officer of Kiniksa Pharmaceuticals and led commercial work for Synageva Biopharma Corp.  Mahoney’s hiring comes after previous CEO Scott Myers officially departed on the company Oct. 29. In addition to Mahoney’s arrival, the company unveiled a couple of new FcRn inhibitors and announced a $185 million private placement. Release > Dren Bio has tapped Amit Mehta, Ph.D., to serve as the company’s chief operating officer and chief business officer. Mehta joins after an 18-year run at Roche’s Genentech, where he was most recently VP and head of business development. Release > Vir Biotechnology has chosen Jennifer Towne, Ph.D., to serve as EVP and chief scientific officer starting Nov. 6. Towne joins Vir from Johnson & Johnson’s Janssen pharmaceutical arm, where she most recently held the role of SVP, immunology discovery and external innovation. Release > Third Harmonic Bio’s chief scientific officer Adrian Ray, Ph.D., has transitioned to the role of scientific adviser, while Chief Financial Officer Robert Ho is set to exit the company Nov. 10. The inflammatory-disease-focused biotech has initiated a search for their successors. Release > Amarin has appointed Jonathan Provoost to serve as EVP, chief legal and compliance officer starting Nov. 15. He most recently served as Tris Pharma’s VP, general counsel and chief compliance officer and has past experience at Mallinckrodt Pharmaceuticals' Ikaria, Kos Pharmaceuticals and Bristol Myers Squibb. Release > Lexicon is bringing on Matthew Cullen to serve as VP of value and access as well as Lisa DeFrancesco to serve as head of investor relations and corporate strategy. Before Lexicon, Cullen was VP of value, access and policy at Apellis Pharmaceuticals, while DeFrancesco most recently served as SVP of investor relations and corporate affairs for Amarin Pharma. Release > Medicenna Therapeutics is reducing its U.S. presence with Chief Financial Officer Jeff Caravella and Chief Business Officer Brent Meadows departing the company. Medicenna will now seek a CFO who is familiar with the Toronto Stock Exchange. Fierce Biotech > RS BioTherapeutics has promoted Michelle Shuffett, M.D., to serve as chief medical officer. Shuffett joined the company in May as SVP of medical and scientific affairs and has previous experience at Boehringer Ingelheim. Release > Sangamo Therapeutics is laying off 162 employees—equivalent to 40% of its U.S. workforce. As part of the restructuring, Chief Operating Officer D. Mark McClung and Chief Scientific Officer Jason Fontenot, Ph.D., will both be heading for the exit. Fierce Biotech > Cell therapy biotech cTRL Therapeutics has chosen Derrell Porter, M.D., to helm the company. Porter most recently served as founder and CEO of Cellevolve Bio and has held past roles at Atara Bio, Gilead Sciences, AbbVie, Amgen and McKinsey & Company. Release > Ocuphire Pharma is welcoming George Magrath, M.D., aboard as CEO. Magrath most recently led Lexitas Pharmaceutical Services through its acquisition by QHP Capital. Release > Storm Therapeutics has selected Marguerite Hutchinson to serve as the biotech’s chief business officer. Hutchinson was previously the chief operating officer and general counsel fo Daiichi Sankyo’s Plexxikon. Release > Myriad Genetics has chosen Sam Raha as chief operating officer, effective Dec. 11. Raha has previously served as Agilent’s president of diagnostics and genomics group and Illumina’s VP of global marketing. Release > Gate Bioscience has exited stealth with $60 million in hand and a roster of leaders onboard, including: Jordi Mata-Fink, Ph.D., co-founder and CEO; Pat Sharp, Ph.D., scientific co-founder and VP of discovery science; Raman Talwar, co-founder and chief technology officer; and Brian Cathers, Ph.D., chief scientific officer. Release > Seattle-based ProfoundBio is adding a couple of key hires to its executive team, naming Erin Lavelle as chief operating officer and chief financial officer and Kevin Hambly as chief business officer. Lori Kunkel, M.D., has also been tapped to lead the company's scientific advisory board. Release > 4DMT has called on Alan Cohen, M.D., to be the therapeutic head of the pulmonary division. One of his most recent roles was as SVP and chief medical officer of gene editing biotech Metagenomi. Release > RNA biotech Senisca is swapping executive positions, with former Chief Operating Officer Sarah Cole, Ph.D., now taking on the role of CEO, while former CEO Kirsty Semple assumes the role of COO. Semple served as launch CEO since January 2020, while Cole joined Senisca in March 2023. Release > Endeavor BioMedicines has elected Paul Frohna, M.D., Ph.D., to serve as its chief medical officer. Frohna joins from ImCheck Therapeutics, where he was CMO and head of R&D, and has held past roles at Bioniz Therapeutics, Receptos, ProFibrix, Fibrogen and Roche’s Genentech. Release > Cognito Therapeutics has chosen Christian Howell as chief commercial officer. Howell joins the neurotech company from Aetion’s medical device and diagnostic group, where he was SVP and general manager. Release > Spatial multi-omics developer Stellaromics has appointed Todd Dickinson as president and CEO. Dickinson previously held technical and commercial executive roles at Illumina and Bionano Genomics and most recently served as CEO of Cantata Bio. Fierce Medtech

SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines, a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer. Dr. Frohna is a physician-scientist with over 20 years of experience in the biotech industry in the fields of translational medicine, clinical trial design, and clinical and regulatory strategy. “We’re pleased to welcome Paul as our Chief Medical Officer, and we look forward to his leadership as we progress our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor BioMedicines. “Paul’s deep experience as a physician-scientist and impressive track record in clinical development and translational medicine will be valuable additions to Endeavor as we advance our programs, including our Phase 2 trial of ENV-101 in idiopathic pulmonary fibrosis (IPF) and the first-in-human trial for our HER3-targeted ADC in oncology.” Dr. Frohna joins Endeavor from ImCheck Therapeutics in Marseille, France, where he served as Chief Medical Officer and Head of Research and Development responsible for overseeing programs in oncology and infectious disease. Prior to ImCheck, he was Chief Medical Officer at Bioniz Therapeutics, where he led clinical and regulatory affairs functions and was responsible for operational oversight of the company's clinical programs in T-cell leukemia and lymphoma as well as autoimmune diseases. Prior to this role, he held senior roles at Receptos Inc., ProFibrix, Inc. and Fibrogen. Dr. Frohna began his biotech career at Genentech where he patented and initially tested the therapeutic approach of B-cell depleting therapy for relapsing and progressive multiple sclerosis. “It is a privilege to join Endeavor as the company enters its next stage of growth," said Dr. Frohna. “I look forward to contributing my clinical development experiences in fibrosis and oncology to demonstrate the therapeutic promise of our pipeline of medicines in order to help patients who deserve better treatments for their deadly diseases.” Over the course of his career, Dr. Frohna has built and led departments and teams responsible for candidate selection, IND/CTA filings, Phase I to III clinical trials and global development partnerships. He has successfully designed and initiated translational and clinical programs for biologics, small molecules and stem cells across multiple therapeutic areas. He played critical roles in multiple development programs including Receptos' ozanimod (Zeposia® marketed by BMS), Profibrix’s Raplixa™ and Genentech's Rituxan®, Tarceva® and Raptiva® programs. Dr. Frohna received his pharmacy degree from the University of Texas at Austin College of Pharmacy, his Ph.D. in Pharmacology from the University of Pennsylvania School of Medicine, and his M.D. from Georgetown University School of Medicine. About Endeavor BioMedicines Endeavor BioMedicines, Inc., is a clinical stage company developing novel therapies for fibrosis and oncology. We combine best-in-class therapeutics with an evolved understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signalling inhibitor currently in Phase 2 studies treating IPF. The second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. At Endeavor, we are an innovative and focused team that has come together to develop therapeutics that help patients feel better and live longer. Please visit us on our website at and on our LinkedIn and X (formerly Twitter) pages. View source version on businesswire.com: Contacts Will Zasadny Evoke Canale Will.zasadny@evokegroup.com Source: Endeavor BioMedicines View this news release online at: